The JAK-STAT pathway: from structural biology to cytokine engineering [0.03%]
结构生物学与细胞因子工程中的JAK-STAT途径研究进展
You Lv,Jianxun Qi,Jeffrey J Babon et al.
You Lv et al.
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway serves as a paradigm for signal transduction from the extracellular environment to the nucleus. It plays a pivotal role in physiological functions, such as...
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer [0.03%]
MYC和KRAS的协同作用：从癌症研究中的历史难题到治疗机遇
Sílvia Casacuberta-Serra,Íñigo González-Larreategui,Daniel Capitán-Leo et al.
Sílvia Casacuberta-Serra et al.
RAS and MYC rank amongst the most commonly altered oncogenes in cancer, with RAS being the most frequently mutated and MYC the most amplified. The cooperative interplay between RAS and MYC constitutes a complex and multifaceted phenomenon, ...
Immune recall enhances cross-reactive antibody longevity after a large wave of SARS-CoV-2 breakthrough infection [0.03%]
免疫回忆增强突破感染后SARS-CoV-2交叉反应抗体的持久性
Dan Li,Qingfei Chu,Kang Li et al.
Dan Li et al.
Biofilms and exopolysaccharides in Pseudomonas aeruginosa: pathogenesis, immune evasion, and lung-brain signaling during pneumonia [0.03%]
铜绿假单胞菌中的生物膜和外多糖：肺炎期间的致病性、免疫逃避及肺-脑信号传导
Shuaibing Zhang,Pierre Stallforth
Shuaibing Zhang
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster [0.03%]
针对XBB.1.5重组蛋白疫苗加强针的稳健中和抗体反应
Bing-Dong Zhan,Xue-Dong Song,Xin Yu et al.
Bing-Dong Zhan et al.
Novel pathomechanistic insights into lysosomal storage disorders: how neuron-intrinsic cGAS-STING signaling drives disease progression [0.03%]
溶酶体贮积病的新病理机制见解：神经元固有cGAS-STING信号通路如何促进疾病进展
Maximilian Frosch,Marco Prinz
Maximilian Frosch
Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation [0.03%]
支链氨基酸转氨酶1通过表观遗传学糖酵解激活介导EGFR-TKI耐药性
Tao Zhang,Zilu Pan,Jing Gao et al.
Tao Zhang et al.
Third-generation EGFR tyrosine kinase inhibitors (TKIs), exemplified by osimertinib, have demonstrated promising clinical efficacy in the treatment of non-small cell lung cancer (NSCLC). Our previous work has identified ASK120067 as a novel...
Ciprian Tomuleasa,Adrian-Bogdan Tigu,Raluca Munteanu et al.
Ciprian Tomuleasa et al.
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and ...
Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies [0.03%]
药物耐受性持久细胞的可塑性与癌症治疗：更有效的抗癌策略革命性方法
Jun He,Zejing Qiu,Jingjing Fan et al.
Jun He et al.
Non-genetic mechanisms have recently emerged as important drivers of anticancer drug resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more and more attention and giving a predominant non-genetic role i...
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial [0.03%]
一项评价吉非替尼（表皮生长因子受体酪氨酸激酶抑制剂）联合阿帕替尼（一种多靶点激酶抑制剂）一线治疗携带EGFR突变的晚期非小细胞肺癌患者的有效性和安全性的Ⅲ期临床研究（FL-ALTER）
Hua-Qiang Zhou,Ya-Xiong Zhang,Gang Chen et al.
Hua-Qiang Zhou et al.
Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor (EGFR) signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: NCT0...